B
Bull
Bull · 25%PALI
$0.77
Scenario price
$1.190
-0.010 (-0.83%)At close
Loading chart…
- High
- 1.220
- Open
- 1.220
- VWAP
- 1.17
- Volume
- 15.12M
- Mkt Cap
- 4.28M
- Low
- 1.100
- Amount
- 17.69M
- EV/EBITDA, TTM
- 0.00
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
AI analysis of Palisade Bio Inc (PALI)
HoldPalisade Bio Inc (PALI) is currently not a strong buy due to its low current price of $1.33 and a concerning RSI of 34.158, indicating potential oversold conditions. While the company has received FDA clearance for its Crohn's disease clinical trial, which could drive future growth, it reported a significant net loss of $10.6 million in Q2 2026, raising concerns about its financial health. The stock has also seen a year-to-date decline of 46.80%, reflecting market skepticism. However, the analyst price targets suggest a potential upside of 350% to 500%, which could be attractive for long-term investors willing to accept the risks involved.
Valuation Metrics
The current forward P/E ratio for Palisade Bio Inc (PALI) is 0.00, compared to its 5-year average forward P/E of -1.36.
Alphio AI Price Scenarios for PALI
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding PALI
Events Timeline
News
9.010-28NewsfilterPalisade Bio Initiates Clinical Trial for PALI-2108
- 8.510-12Newsfilter
Palisade Bio Showcases PALI-2108 Progress at ACG Meeting
7.510-12stocktwitsBiotech Firms Set to Release Key Data This Week
9.009-23NASDAQ.COMPalisade Bio Receives FDA Clearance for Crohn's Disease Clinical Trial
9.508-11NASDAQ.COMPalisade Bio Reports Wider Q2 Loss Amid Clinical Advancements
PALI FAQ — answered by Alphio AI
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Palisade Bio Inc (PALI) is currently not a strong buy due to its low current price of $1.33 and a concerning RSI of 34.158, indicating potential oversold conditions. While the company has received FDA clearance for its Crohn's disease clinical trial, which could drive future growth, it reported a significant net loss of $10.6 million in Q2 2026, raising concerns about its financial health. The stock has also seen a year-to-date decline of 46.80%, reflecting market skepticism. However, the analyst price targets suggest a potential upside of 350% to 500%, which could be attractive for long-term investors willing to accept the risks involved.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.